The warrant amendments create a binary catalyst tied to FDA approval of CGuard Prime 80 cm, expected in Q4 2026. If approved, holders have 20 trading days to exercise at $0.7674, potentially adding ~$11M in cash but also diluting existing shareholders by up to ~14.3M shares. Monitor FDA decision timeline and any subsequent insider exercise patterns.
Price Chart
Executive Summary
InspireMD amended existing Series J and Series K warrants with certain holders, lowering the exercise price to $0.7674 per share (the September 18 closing price) and tying the termination date to FDA approval of CGuard Prime 80 cm (anticipated Q4 2026). The amendments cover ~4.8M Series J shares (50% of participating holders' J warrants) and all ~9.5M Series K shares held by participants, with potential gross proceeds of up to $11 million if exercised in full. No new warrants or additional shares were issued.
Key Financial Metrics
Key Facts
- Amendments apply to ~4.8M Series J shares (50% of participating holders' J warrants) and all ~9.5M Series K shares held by participating holders.
- Exercise price reduced to $0.7674 per share, equal to the Nasdaq Official Closing Price on September 18, 2026.
- Termination date set to earlier of May 15, 2028 or 20 trading days after FDA approval announcement for CGuard Prime 80 cm.
- Potential gross proceeds of up to $11 million if amended warrants are exercised in full.
- Certain holders entering into amendments are also members of the board of directors.
- No additional warrants or shares were issued in connection with the amendments.
- Original exercise price of $1.3827 per share and original termination triggers remain unchanged for the other 50% of Series J shares and for non-participating holders.
Financial Impact
Potential gross proceeds of up to $11 million from warrant exercises, contingent on FDA approval of CGuard Prime 80 cm.
Risk Factors
- FDA approval of CGuard Prime 80 cm may be delayed or denied, leaving warrants unexercised and no capital raised.
- Full exercise of ~14.3M shares would cause significant dilution to existing shareholders.
- The company has a history of losses and going concern uncertainty, as noted in the forward-looking statements.
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043488 |
| Exhibit: ex4-1.htm | 0001493152-26-043488 |
| Exhibit: ex4-2.htm | 0001493152-26-043488 |
| Exhibit: ex99-1.htm | 0001493152-26-043488 |
| Document: 0001493152-26-043488-index-headers.html | 0001493152-26-043488 |
| Document: 0001493152-26-043488-index.html | 0001493152-26-043488 |
| Document: 0001493152-26-043488.txt | 0001493152-26-043488 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Sep 21, 2026 5w ago | Press Release | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Aug 17, 2026 10w ago | 8-K | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 17, 2026 10w ago | Press Release | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 10, 2026 11w ago | Press Release | $0.8500 $0.8816 | ▲ +3.72% | ▲ +4.12% | $0.4500 (−47.06%) |
Jul 29, 2026 12w ago | 8-K | $0.6718 $0.7222 | ▲ +7.50% | ▲ +3.88% | $0.4500 (−33.02%) |
Jul 23, 2026 13w ago | 8-K | $0.6835 $0.6718 | ▲ +1.71% | ▲ +2.09% | $0.4500 (+34.16%) |
Jul 2, 2026 16w ago | 8-K | $0.6990 $0.7121 | ▲ +1.87% | ▲ +0.94% | $0.4500 (−35.62%) |
May 21, 2026 22w ago | Insider Cluster | $1.00 $0.9900 | ▼ −1.00% | ▼ −2.66% | $0.4500 (−55.00%) |
May 15, 2026 23w ago | Insider Cluster | $1.05 $0.9500 | ▼ −9.52% | ▼ −11.14% | $0.4500 (−57.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers